T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer

This study has been completed.
Information provided by (Responsible Party):
Franziska Eckert, University Hospital Tuebingen
ClinicalTrials.gov Identifier:
First received: June 16, 2011
Last updated: August 15, 2013
Last verified: August 2013

Immunological effects of radiotherapy have been described before, but not evaluated in a time-dependant manner.

In order to identify a possible time frame for combination therapies, white blood cells are isolated of samples taken at different time points before during and after standard radiotherapy in patients with localised prostate cancer. The overall activity of the T-cell-system as well as tumor-specific T-cell-response are evaluated.

Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Changes of T-cell-immune-status During Curative Radiotherapy in Prostate Cancer

Resource links provided by NLM:

Further study details as provided by University Hospital Tuebingen:

Primary Outcome Measures:
  • T-cell-immunity in time-course [ Time Frame: During and 3-6 months after radiotherapy ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
Peripheral blood mononuclear cells and serum are frozen and stored.

Enrollment: 22
Study Start Date: March 2011

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients undergoing standard radiotherapy for localised prostate cancer at the University Hospital of Tuebingen

Inclusion Criteria:

  • Localised prostate cancer (node negative)
  • definitive radiotherapy
  • informed consent

Exclusion Criteria:

  • medication including steroids or immunosuppressants
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01376674

Department of Radiation Oncology
Tuebingen, Germany, D-72076
Sponsors and Collaborators
University Hospital Tuebingen
Principal Investigator: Cihan Gani, M.D. University Hospital Tuebingen
Study Director: Franziska Eckert, MD University Hospital Tuebingen
  More Information

Responsible Party: Franziska Eckert, M.D., University Hospital Tuebingen
ClinicalTrials.gov Identifier: NCT01376674     History of Changes
Other Study ID Numbers: UKT_RO_01 
Study First Received: June 16, 2011
Last Updated: August 15, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University Hospital Tuebingen:
prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on April 27, 2016